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Summary
Background Results of several trials of antioxidant use during pregnancy have not shown a reduction in pre-eclampsia, 
but the eﬀ ect in women with diabetes is unknown. We aimed to assess whether supplementation with vitamins C and 
E reduced incidence of pre-eclampsia in women with type 1 diabetes.
Methods We enrolled women from 25 UK antenatal metabolic clinics in a multicentre randomised placebo-controlled 
trial. Eligibility criteria were type 1 diabetes preceding pregnancy, presentation between 8 weeks’ and 22 weeks’ 
gestation, singleton pregnancy, and age 16 years or older. Women were randomly allocated in a 1:1 ratio to receive 
1000 mg vitamin C and 400 IU vitamin E (α-tocopherol) or matched placebo daily until delivery. The randomisation 
sequence was stratiﬁ ed by centre with balanced blocks of eight patients. All trial personnel and participants were 
masked to treatment allocation. The primary endpoint was pre-eclampsia, which we deﬁ ned as gestational 
hypertension with proteinuria. Analysis was by modiﬁ ed intention to treat. This study is registered, 
ISRCTN27214045.
Findings Between April, 2003, and June, 2008, 762 women were randomly allocated to treatment groups (379 vitamin 
supplementation, 383 placebo). The primary endpoint was assessed for 375 women allocated to receive vitamins, and 
374 allocated to placebo. Rates of pre-eclampsia did not diﬀ er between vitamin (15%, n=57) and placebo (19%, 70) 
groups (risk ratio 0·81, 95% CI 0·59–1·12). No adverse maternal or neonatal outcomes were reported.
Interpretation Supplementation with vitamins C and E did not reduce risk of pre-eclampsia in women with type 1 
diabetes. However, the possibility that vitamin supplementation might be beneﬁ cial in women with a low antioxidant 
status at baseline needs further testing.
Funding The Wellcome Trust.
Introduction
Pre-eclampsia is a multisystem disorder of pregnancy 
that is characterised by pregnancy-induced or gestational 
hypertension and new-onset proteinuria during the 
second half of pregnancy.1 Recognised risk factors are 
nulliparity, age younger than 20 years or older than 
40 years, obesity, history of pre-eclampsia, multiple 
pregnancy, and pre-existing disorders such as chronic 
hypertension, renal disease, autoimmune disease, 
antiphospholipid syndrome, and diabetes mellitus.2 Pre-
eclampsia results in serious maternal complications 
such as eclampsia and HELLP (haemolysis, elevated 
liver enzymes and low platelets) syndrome, and is a 
foremost cause of maternal death.3 Moreover, since 
delivery is the only cure, up to 15% of preterm births are 
associated with pre-eclampsia, with a consequent 
increase in infant mortality and morbidity.4 The global 
prevalence is around 4%,3 but the rate is raised two to 
four times in women with type 1 diabetes, and increases 
with complexity of diabetes.5–7
The hypothesis that oxidative stress plays a key part in 
pathogenesis of pre-eclampsia was proposed in the late 
1980s,8 and has since been the focus of much research.9,10 
Diabetes mellitus, speciﬁ cally type 1 diabetes, is associated 
with increased oxidative stress and antioxidant 
depletion,11,12 which is partly related to prevailing blood 
glucose concentrations.13 Increased oxidative stress in 
pregnant women with diabetes14,15 might account for rates 
of pre-eclampsia that are two to four times higher in this 
group, especially in those with diabetes-related 
complications,5–7 and lends support to the postulated role 
of oxidative stress in pathophysiology of the disorder in 
diabetes-associated pregnancy.16
In a small randomised placebo-controlled trial,17 
supplementation with vitamins C and E was associated 
with a reduction in rate of pre-eclampsia from 17% to 8% 
(adjusted odds ratio 0·39, 95% CI 0·17–0·90) in 
283 women at high risk of developing the disorder. These 
results added to existing evidence for a role of oxidative 
stress in pathogenesis of pre-eclampsia, and led to several 
large trials of antioxidant treatment for prevention of pre-
eclampsia.18–24 The results of these trials have shown no 
beneﬁ t of vitamin C and E supplementation during 
pregnancy;18,19,21–24 however, only three included women 
with diabetes, and in each instance these groups were 
small and poorly characterised.18,19,23 Since pre-eclampsia 
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is likely to be a heterogeneous disease,9 pathogenesis 
could vary between women with diﬀ erent risk factors. 
Furthermore, in view of the increase in oxidative stress 
and antioxidant depletion that occur in diabetes, a 
beneﬁ cial eﬀ ect of antioxidant supplementation is 
plausible in this group of patients.
We designed the Diabetes and Pre-eclampsia Inter-
vention Trial (DAPIT) to assess whether supplement ation 
with vitamins C and E reduced incidence of pre-eclampsia 
in women with type 1 diabetes.20
Methods
Study design and patients
DAPIT was a multicentre, randomised, placebo-
controlled, parallel-group trial. Women were recruited 
from 25 antenatal metabolic clinics across Northern 
Ireland, Scotland, and northwest England between April, 
2003, and June, 2008. The last baby was delivered in 
December, 2008. Eligibility criteria were type 1 diabetes 
preceding pregnancy, presentation between 8 weeks’ and 
22 weeks’ gestation, singleton pregnancy, and age 16 years 
or older. Women were excluded if they did not give 
consent, were enrolled in another research study, were 
being treated with warfarin, or were known to misuse 
drugs. Women taking vitamin supplements were 
excluded only if these contained 500 mg or more vitamin 
C or 200 IU or more vitamin E daily. Women with chronic 
hypertension were included in the trial. The West 
Midlands multicentre research ethics committee provided 
ethics approval (MREC 02/7/016). Participants gave 
written informed consent and had at least 48 h to review 
the patient information sheet.
Randomisation and masking
Participants were randomly allocated in a 1:1 ratio to receive 
1000 mg vitamin C and 400 IU vitamin E or matched 
placebo daily from between 8 and 22 weeks’ gestation until 
delivery. Vitamin C and identical placebo (calcium 
carbonate, microcrystalline cellulose, maltrodextrin, and 
stearic acid) tablets were manufactured by Thompson & 
Capper (Astmoor, Runcorn, Cheshire, UK). Natural-source 
vitamin E (α-tocopherol) and identical placebo (olive oil) 
capsules were manufactured by Eurocaps Limited 
(Dukestown, Tredegar, Gwent, UK). Victoria 
Pharmaceuticals (The Royal Hospitals, Belfast, UK) 
packaged tablets and capsules, 120 per bottle, according to 
a randomisation sequence generated in advance by Victoria 
Pharma ceuticals using PRISYM ID software (version 
1.0009). The randomisation sequence was stratiﬁ ed by 
centre with balanced blocks of eight patients, and was held 
by Victoria Pharmaceuticals. Individual sealed envelopes 
containing treatment allocations were given to trial 
pharmacists in every centre, allowing treatment group to 
be revealed in a clinical emergency. Treatment allocation 
was masked from all trial personnel and participants until 
trial completion.
Procedures
Eligible women who gave consent were assigned the next 
available number at that centre by research midwives, 
and given their ﬁ rst supply of trial drugs—bottles of 
vitamin C tablets and vitamin E capsules (vitamin group) 
or bottles of placebos (placebo group)—along with a 7-day 
pill dispenser to aid adherence. Participants were 
instructed to take one tablet and one capsule daily until 
delivery, and to leave unused pills in the bottles. 
Participants attended trial visits at 26 (within 2) weeks’ 
and 34 (within 2) weeks’ gestation, at which times tablets 
and capsules were counted and the next supply dispensed. 
Unused tablets and capsules were collected during 
delivery admission or at the 6-week postnatal trial visit, 
or were returned in postage prepaid envelopes.
Blood pressure at randomisation was measured with a 
British Hypertension Society validated automated 
instrument, (Omron M5-I, Omron Healthcare, West 
Sussex, UK). After the participant had been seated for 
5 min, the average of two measurements taken 3 min apart 
was recorded. Biological samples obtained at baseline, 
26 weeks’, and 34 weeks’ gestation were batch analysed at 
the end of the study at the central laboratory (Queen’s 
University, Belfast) for plasminogen activator inhibitor 
type 1 (PAI-1) and type 2 (PAI-2), plasma ascorbate 
concentrations, serum concentrations of α-tocopherol 
(expressed per mmol of serum cholesterol), serum total 
cholesterol, HbA1c, and urine microalbumin and creatinine. 
Laboratory analyses are detailed in the webappendix. 
When possible, follow-up data were obtained for study 
participants at routine clinic visits 6 weeks after delivery 
and for infants at 8 week postnatal checks with their 
paediatrician, family doctor, or health visitor. These data 
Figure 1: Trial proﬁ le
  379 allocated to vitamin C and vitamin E   383 allocated to placebo
  762 randomised
        0 lost to follow-up          1 lost to follow-up 
            (withdrew consent)
1621 women assessed for eligibility
    859 excluded
             137 did not meet inclusion criteria
             187 had a miscarriage during assessment timeframe
             450 refused to participate
                85 other
   379 women completed the trial   382 women completed the trial
        4 pregnancies ≤20 weeks’ 
            gestation
        8 pregnancies ≤20 weeks’ 
            gestation
   375 women analysed for pre-eclampsia   374 women analysed for pre-eclampsia
See Online for webappendix
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were measurement of weight, length, and head 
circumference and assessment of ﬁ xation, following, 
smiling, head control, tone, tendon reﬂ exes, heart 
murmurs, and congenital abnormalities.
The primary outcome was pre-eclampsia, which we 
deﬁ ned as gestational hypertension with proteinuria in 
accordance with the International Society for the Study of 
Hypertension in Pregnancy guidelines.1 Gestational 
hypertension was deﬁ ned as two diastolic blood pressure 
readings of 90 mm Hg or more at least 4 h apart, or one 
reading of at least 110 mm Hg, occurring after 20 weeks’ 
gestation or up to 48 h postnatally and excluding labour. 
Proteinuria was deﬁ ned as a result of at least 1+ for dipstick 
analysis of a midstream specimen on two or more 
occasions or more than 300 mg urinary protein per 24 h. 
For women with diastolic blood pressure greater than 
90 mm Hg at the ﬁ rst antenatal visit, superimposed pre-
eclampsia was deﬁ ned as the development of proteinuria 
and a rise of at least 10 mm Hg from the ﬁ rst recorded 
antenatal diastolic blood pressure on two occasions at least 
4 h apart or one reading of at least 110 mm Hg, occurring 
from 20 weeks’ gestation until 48 h postnatally and 
excluding labour. For women with pre-existing proteinuria, 
diagnosis was made by a doubling of proteinuria on the 
basis of dipstick or quantitative measurements or on 
clinical or biochemical grounds by identiﬁ cation of one 
additional feature of pre-eclampsia (eg, HELLP syndrome, 
eclampsia). Staﬀ  in the trial centre reviewed all participants 
with hypertension. Additionally, diagnosis was 
independently conﬁ rmed by three senior clinicians, who 
were unaware of treatment allocation.
Secondary outcomes were placental and endothelial 
function as established by PAI-1 to PAI-2 ratio, gestational 
hypertension, and birthweight centile as calculated from 
customised birthweight charts.25 We prespeciﬁ ed several 
additional maternal and neonatal outcomes, including 
miscarriage, maternal death, obstetric complications and 
other adverse outcomes, fetal malformation, gestational 
age at delivery, and admission to a neonatal care unit. We 
expressed growth measures (weight, length, head 
circumference) at birth and postnatal follow-up 
(6–12 weeks of age) as SD scores using the 1990 British 
Growth Standard.26
Statistical analysis
On the assumption of a 20% rate of pre-eclampsia, a study 
size of 756 women had greater than 80% power to detect 
a 40% reduction (from 20% to 12%) as signiﬁ cant (p<0·05; 
two-tailed). We did seven interim analyses for the primary 
endpoint using the Haybittle-Peto method27 and presented 
results to the independent data monitoring committee. 
Analysis of the primary endpoint was by modiﬁ ed 
intention to treat, for all pregnancies of more than 
20 weeks’ gestation. We undertook 11 predeﬁ ned subgroup 
analyses for the primary endpoint: baseline control of 
diabetes; HbA1c less than 7%, 7–8%, and more than 8%; 
baseline antioxidant status (vitamin E <3 μmol/mmol 
cholesterol, 3–5 μmol/mmol cholesterol, and >5 μmol/
mmol cholesterol; vitamin C <10 μmol/L, 10–30 μmol/L, 
and >30 μmol/L); and current smoking (yes or no).
Treatment group comparisons were summarised as 
diﬀ erences in means or risk ratios (with 95% CIs) and 
independent samples t tests and χ² or Fisher’s exact tests 
were applied. To allow for multiple comparisons, we used 
a strict signiﬁ cance level (p<0·01) for secondary 
outcomes. Log transformations were applied in an 
attempt to normalise the distribution of PAI-1 to PAI-2 
ratio, but comparisons were done with the Mann-Whitney 
U test. SPSS (version 17) was used for all analyses.
This study is registered, ISRCTN27214045.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Vitamins C and E (N=379) Placebo (N=383)
Age (years) 29·5 (5·6) 29·6 (5·7)
Gestation (weeks) 14·3 (3·6) 14·2 (3·4)
Body-mass index (kg/m2) 27·6 (5·4) 27·4 (4·6)
Ethnic origin
White 364 (96%) 371 (97%)
Black 3 (1%) 4 (1%)
Asian 6 (2%) 5 (1%)
Other/not known 6 (2%) 3 (1%)
12 years or fewer in full-time education 140 (37%) 159 (42%)
Primigravida   190 (50%) 188 (49%)
Blood pressure (mm Hg)
Systolic 119·2 (12·2) 118·4 (11·6)
Diastolic 74·6 (8·7) 74·5 (8·4)
Antihypertensive treatment before this pregnancy 21 (6%) 40 (10%)
History of hypertension before pregnancy 46 (12%) 66 (17%)
History of pre-eclampsia in previous pregnancy 6 (2%) 20 (5%)
Diabetes
Duration (years) 14·0 (8·3) 15·0 (8·0)
HbA1c at randomisation (%) 7·2 (0·9) 7·2 (1·0)
Total daily insulin dose at randomisation (units) 58 (44–73) 56 (43–72)
Renal status before this pregnancy
Normal 355 (94%) 338 (88%)
Microalbuminuria 13 (3%) 23 (6%)
Macroalbuminuria 1 (<1%) 3 (1%)
24-h urinary protein more than 3 g per 24 h 0 4 (1%)
Not known 10 (3%) 15 (4%)
Albumin-to-creatinine ratio at randomisation (mg/mmol) 0·71 (0·38–1·28) 0·73 (0·41–1·95) 
Current smoker 75 (20%) 74 (19%)
Taking aspirin at randomisation 28 (7%) 31 (8%)
Taking multivitamin supplements at randomisation 38 (10%) 35 (9%)
Data are mean (SD), number (%), or median (IQR).
Table 1: Baseline maternal characteristics
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Results
Figure 1 shows the trial proﬁ le. Of the 762 women 
enrolled, 379 were randomly allocated to receive vitamins 
C and E and 383 to placebo. Outcome data were available 
for 761 women (379 vitamin, 382 placebo), and 749 women 
were assessed for pre-eclampsia, by original assigned 
group (375 vitamin, 374 placebo). There were 12 deviations 
from the inclusion and exclusion criteria—eight women 
were enrolled outside the 22-week cutoﬀ  for gestation (all 
were within 4 days of this threshold) and four patients 
were later reclassiﬁ ed as having type 2 diabetes. All 
12 women were included in the analysis.
Although most maternal baseline characteristics did 
not diﬀ er between groups, history of pre-eclampsia, 
hypertension, antihypertensive treatment, and micro-
albuminuria were more common in the placebo group 
than in the vitamin group (table 1). On the basis of counts 
of returned pills after delivery (or at the 34-week visit if 
no count was available after delivery, n=45) from 
618 women, 524 (85%) took at least 50% of their tablets, 
434 (70%) took 80% or more, and 237 (38%) took all their 
tablets; 17 (3%) did not take any. Estimated percentage 
adherence did not diﬀ er between groups (vitamin C, 
median 95% [IQR 75–100] vs placebo, 96% [74–100]; 
vitamin E, 93% [78–100] vs placebo, 93% [74–100]).
Overall, 127 (17%) women developed pre-eclampsia. 
Risk of pre-eclampsia did not diﬀ er between vitamin and 
placebo groups (table 2). There were no signiﬁ cant 
diﬀ erences between groups in risk of gestational 
hypertension or birthweight lower than the tenth centile 
for gestational age (table 2). PAI-1 to PAI-2 ratios did not 
diﬀ er between groups at baseline (p=0·40), 26 weeks 
(p=0·32), and 34 weeks (p=0·78) (ﬁ gure 2).
We noted no signiﬁ cant diﬀ erences between vitamin and 
placebo groups for any maternal outcome, including 
delivery after a hypertension-related admission before 34 or 
37 weeks, but fewer babies were born preterm (<37 weeks’ 
gestation) in the vitamin group than in the placebo group 
(table 3). There were no signiﬁ cant diﬀ erences between 
vitamin and placebo groups for any clinical neonatal 
outcome including fetal malformation, fetal loss, infant 
death, or miscarriage. Rates of admission to neonatal care, 
including intensive care, were similar in both groups, as 
were rates of respiratory diagnoses and other complications 
(table 3). Table 4 shows mean birthweights for both vitamin 
and placebo groups; risk of birthweights of 2500 g or less 
(RR 0·82, 95% CI 0·56–1·20) and 4000 g or more (1·25, 
0·95–1·64) did not diﬀ er between groups. No signiﬁ cant 
diﬀ erences were found in SD scores for weight, length, or 
head circumference between infants from each group at 
birth or follow-up (table 4). We noted no adverse events or 
side eﬀ ects attributable to supplementation with vitamin C 
or E in mothers or infants.
Mean plasma ascorbate concentrations (vitamin, 44·4 
[SD 26·0] μmol/L vs placebo, 44·2 [26·0] μmol/L) and 
cholesterol-corrected serum α-tocopherol concentrations 
(6·15 [1·24] μmol/mmol vs 6·19 [1·20] μmol/mmol) were 
similar at baseline in both groups (ﬁ gure 3). Blood 
Vitamins C and E (N=379) Placebo (N=382) Risk ratio (95% CI) p value
Primary outcome
Pre-eclampsia* 57/375 (15%) 70/374 (19%) 0·81 (0·59–1·12) 0·20
Secondary outcomes 
Gestational hypertension* 42/375 (11%) 41/374 (11%) 1·02 (0·68–1·53) 0·92
Birthweight lower than the tenth centile for gestational age25 23/373 (6%) 36/372 (10%) 0·64 (0·39–1·05) 0·08
Data are n/N (%) or risk ratio (95% CI). *Analysis included all pregnancies greater than 20 weeks’ gestational age.
Table 2: Primary and secondary clinical outcomes
Figure 2: PAI-1 to PAI-2 ratio by weeks’ gestation
PAI-1 to PAI-2 ratio in vitamin and placebo groups at baseline, 26 weeks’, and 34 weeks’ gestation (within 2 weeks). 
Boxes show IQRs, and medians are shown by horizontal lines. Vertical lines extend to the highest and lowest values, 
but outliers (results exceeding the upper quartile by more than 1·5 times the IQR) are identiﬁ ed as individual symbols. 
Values greater than 5 are shown by arrows at the top of the ﬁ gure. PAI=plasminogen activator inhibitor.
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Vitamins C and E (N=379) Placebo (N=382) Risk ratio (95% CI) p value
Maternal
Miscarriage 4/379 (1%) 4/382 (1%) 1·01 (0·25–4·00) 1·00
Elective termination 1/379 (<1%) 5/382 (1%) 0·20 (0·02–1·72) 0·22
Maternal death 0/379 1/382 (<1%) NA 1·00
Delivery following a hypertension-related admission
<34 weeks’ gestation 13/375 (3%) 12/374 (3%) 1·08 (0·50–2·34) 0·84
<37 weeks’ gestation 43/375 (11%) 48/374 (13%) 0·89 (0·61–1·31) 0·57
Obstetric complications
Eclampsia 1/375 (<1%) 2/374 (1%) 0·50 (0·05–5·48) 0·62
HELLP syndrome 3/375 (1%) 2/374 (1%) 1·50 (0·25–8·90) 1·00
Pulmonary oedema 1/375 (<1%) 2/374 (1%) 0·50 (0·05–5·48) 0·62
Placental abruption 5/375 (1%) 7/374 (2%) 0·71 (0·23–2·22) 0·56
PPROM (<37 weeks) 23/375 (6%) 31/374 (8%) 0·74 (0·44–1·24) 0·25
Other adverse outcomes
DBP >110 mm Hg 13/374 (3%) 15/375 (4%) 0·87 (0·42–1·80) 0·71
>5 g proteinuria per day 9/375 (2%) 9/373 (2%) 0·99 (0·40–2·48) 0·99
Platelets <100 000 per mL 4/368 (1%) 4/366 (1%) 0·99 (0·25–3·95) 1·00
Abnormal concentrations of alanine and aspartate aminotransferases 23/368 (6%) 33/371 (9%) 0·70 (0·42–1·17) 0·17
Polyhydramnios 30/374 (8%) 26/373 (7%) 1·15 (0·69–1·91) 0·59
Neonatal
Fetal loss or infant death
Late fetal loss 1/379 (<1%) 0/382 NA 1·00
Antepartum stillbirth 9/379 (2%) 8/382 (2%) 1·13 (0·44–2·91) 0·79
Neonatal death 2/364 (1%) 3/366 (1%) 0·67 (0·11–3·99) 1·00
Birthweight for gestational age²⁵
<5th centile 15/373 (4%) 24/372 (6%) 0·62 (0·33–1·17) 0·14
>90th centile 199/373 (53%) 186/372 (50%) 1·07 (0·93–1·23) 0·36
Gestational age at delivery
<28 weeks 5/375 (1%) 2/374 (1%) 2·49 (0·49–12·8) 0·45
<34 weeks 35/375 (9%) 36/374 (10%) 0·97 (0·62–1·51) 0·89
<37 weeks 126/375 (34%) 152/374 (41%) 0·83 (0·69–1·00) 0·046
Major fetal malformation 12/378 (3%) 17/382 (4%) 0·71 (0·35–1·47) 0·36
Admission to neonatal intensive care unit
Overall 197/363 (54%) 205/365 (56%) 0·97 (0·85–1·10) 0·61
Level 1 (intensive care) 28/363 (8%) 39/365 (11%) 0·72 (0·45–1·15) 0·17
Level 2 (high dependency care) 42/363 (12%) 54/365 (15%) 0·78 (0·54–1·14) 0·20
Level 3 (special care in NICU) 192/363 (53%) 197/365 (54%) 0·98 (0·86–1·12) 0·77
Special care provided on postnatal ward 243/363 (67%) 225/365 (62%) 1·09 (0·97–1·21) 0·14
Assisted ventilation (endotracheal tube)  20/364 (5%) 25/364 (7%) 0·80 (0·45–1·41) 0·44
Phototherapy 68/362 (19%) 87/363 (24%) 0·78 (0·59–1·04) 0·09
Respiratory distress syndrome 26/363 (7%) 32/364 (9%) 0·81 (0·50–1·34) 0·42
Complications
Necrotising enterocolitis 0/362 3/365 (1%) NA 0·25
Seizures necessitating use of anticonvulsant drugs 3/362 (1%) 2/364 (1%) 1·51 (0·25–8·97) 0·69
Retinopathy of prematurity 1/361 (<1%) 2/365 (1%) 0·51 (0·05–5·55) 1·00
Bacteraemia (proven) 6/363 (2%) 14/364 (4%) 0·43 (0·17–1·11) 0·07
Chronic lung disease* 2/363 (1%) 5/363 (1%) 0·40 (0·08–2·05) 0·45
Data are n/N (%) or risk ratio (95% CI). HELLP=haemolysis, elevated liver enzymes, low platelets. PPROM=preterm premature rupture of membranes. DBP=diastolic blood 
pressure. NICU=neonatal intensive care unit. *Chronic lung disease was deﬁ ned as a need for oxygen at 36 weeks’ corrected age, for infants born at less than 32 weeks’ 
gestation, or the need for oxygen after day 28 for infants born at 32 weeks’ gestation or more.
Table 3: Maternal and neonatal outcomes
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samples were available for plasma ascorbate analysis in 
590 (77%) patients at 26 weeks (299 vitamin, 291 placebo) 
and 511 (67%) at 34 weeks (263 vitamin, 248 placebo), and 
for serum α-tocopherol analysis in 614 (81%) patients at 
26 weeks (309 vitamin, 305 placebo) and 536 (70%) at 
34 weeks (267 vitamin, 269 placebo). Concentrations of 
both vitamins were signiﬁ cantly higher in the vitamin 
group than in the placebo group at 26 weeks’ and 
34 weeks’ gestation (p<0·0001) (ﬁ gure 3).
Table 5 compares rates of pre-eclampsia in predeﬁ ned 
subgroup analyses. Rates of pre-eclampsia did not vary 
with baseline control of diabetes or baseline smoking 
status. However, fewer women with baseline plasma 
ascorbate concentrations lower than 10 μmol/L 
developed pre-eclampsia in the vitamin group than in 
the placebo group. Furthermore, fewer women with 
baseline serum α-tocopherol of 3–5 μmol/mmol 
cholesterol developed pre-eclampsia in the vitamin 
group compared with placebo.
Discussion
In this multicentre, randomised, placebo-controlled trial, 
daily supplementation with vitamins C and E from early to 
mid pregnancy did not reduce risk of pre-eclampsia, 
gestational hypertension, or low birthweight infants in 
women with type 1 diabetes, nor did it reduce the PAI-1 to 
PAI-2 ratio, which is a measure of endothelial activation. 
However, in two of 11 prespeciﬁ ed subgroup analyses, risk 
of pre-eclampsia was signiﬁ cantly reduced in women with 
low antioxidant status at baseline who were randomly 
allocated to the vitamin group compared with women of 
similar antioxidant status assigned to placebo, although 
the numbers were small and neither analysis was 
signiﬁ cant with the more stringent interaction test that is 
recommended by CONSORT.28 We noted no evidence that 
antioxidant supplementation was associated with any harm 
to mother or baby; indeed, almost all of the trends were in 
the direction of beneﬁ t to the supplemented group.
Several large trials of antioxidant supplementation for 
prevention of pre-eclampsia in women at both low22,23,24 
and high risk have already been completed.18,19,21,23 All used 
similar doses of vitamins C and E, with women randomly 
allocated to treatment groups in the late ﬁ rst or second 
Vitamins C and E Placebo Mean diﬀ erence (95% CI) p value
N Mean (SD) N Mean (SD)
Birthweight (g) 373 3435 (802) 372 3355 (800) 80 (–35 to 195) 0·17
Birthweight SD score 372 1·37 (1·44) 371 1·28 (1·51) 0·09 (–0·12 to 0·30) 0·39
Birth length SD score 231 1·30 (1·75) 222 1·39 (1·51) –0·08 (–0·38 to 0·22) 0·60
Birth head circumference SD score 349 0·90 (1·25) 338 0·74 (1·28) 0·16 (–0·03 to 0·35) 0·10
Follow-up weight SD score 292 0·72 (1·13) 289 0·61 (1·12) 0·11 (–0·07 to 0·30) 0·23
Follow-up length SD score 264 0·71 (1·15) 261 0·51 (1·19) 0·21 (0·01 to 0·41) 0·04
Follow-up head circumference SD score 270 0·62 (1·10) 263 0·46 (1·29) 0·16 (–0·04 to 0·37) 0·12
Data are number, mean (SD), or mean diﬀ erence (95% CI).
Table 4: Growth measures at birth and at postnatal follow-up (6–12 weeks of age)
Figure 3: Plasma ascorbate and serum α-tocopherol concentrations, by 
weeks’ gestation 
Mean plasma ascorbate (A) and serum α-tocopherol (B) concentrations in 
vitamin and placebo groups at baseline, 26 weeks’, and 34 weeks’ gestation 
(within 2 weeks). Error bars show 95% CIs.
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trimester. The ﬁ ndings have been uniformly negative for 
pre-eclampsia reported as a primary18,19,21,22 or secondary 
outcome.23,24 Increased rates of low birthweight,18 
gestational hypertension,23,24 fetal loss,23 stillbirth18 or 
premature rupture of membranes21,23 were reported by 
investigators in some trials, but were not conﬁ rmed across 
all studies, and thus their signiﬁ cance remains uncertain. 
A further diﬃ  culty with some of these trials is the 
heterogeneous nature of the population under study.18,19,21,23 
DAPIT diﬀ ers from previous trials because it focused on 
the role of antioxidants in a homogeneous group of 
carefully characterised women with type 1 diabetes.
In agreement with the WHO trial,19 and by contrast with 
other trials,18,21–24 we noted no evidence of harm attributable 
to antioxidant supplementation either in mothers or 
infants. A Cochrane review of vitamin C supplementation 
in pregnancy raised concerns about a possible increased 
risk of preterm birth in women supplemented with 
vitamin C alone or combined with other supplements.29 
In our trial, women assigned to the vitamin group were 
less likely to deliver preterm (<37 weeks’ gestation) than 
were women taking placebo. The VIP trial raised concerns 
about the eﬀ ect of antioxidant supplementation on growth 
restriction in a subgroup of women with diabetes.18 Our 
trial, in a much larger diabetic population than the VIP 
trial subgroup, did not conﬁ rm this ﬁ nding. By contrast, 
women in DAPIT assigned to receive vitamins tended to 
have a reduced risk of having a baby with birthweight 
lower than the tenth centile for gestational age. 
Additionally, the small subgroup with diabetes in the VIP 
trial contained women with either type 1 or type 2 diabetes, 
whereas DAPIT recruited only women with type 1 diabetes. 
Although the pathways involved in pathogenesis of pre-
eclampsia could diﬀ er between women with type 1 and 
type 2 diabetes, the VIP result was more likely to have 
been a chance ﬁ nding, since the diabetes group in this 
trial was one of nine subgroups analysed.
Women in our study with a low antioxidant status at 
baseline (plasma ascorbate <10 μmol/L or serum 
α-tocopherol ≤5 μmol/mmol cholesterol) who were 
assigned to receive vitamins had a reduced risk of pre-
eclampsia compared with similar women assigned to 
receive placebo. Though small, these subgroups were 
almost mutually exclusive. No analysis of this type has 
been reported for previous trials. Previous negative studies 
are likely to have been done in women with adequate 
baseline antioxidant status.18 The exception might have 
been the WHO trial,19 in which the study population was 
from developing countries and which did not show any 
beneﬁ cial eﬀ ect of antioxidant supplementation. However, 
no measurements of ascorbate or α-tocopherol were 
available, and women were only presumed to have low 
antioxidant status on the basis of data from previous studies 
in the participating clinics. Recruitment of a suﬃ  cient 
cohort of women with low baseline antioxidant status to a 
randomised trial to conﬁ rm our ﬁ nding would be diﬃ  cult. 
However, further characterisation of these patients in an 
eﬀ ort to identify women potentially at risk of antioxidant 
depletion in the clinical setting will be of interest.
Finally, how should these ﬁ ndings be interpreted? The 
initial report of a beneﬁ cial eﬀ ect of antioxidant vitamins17 
could have been a chance ﬁ nding. Subsequent trials 
recruited women with various risk factors for pre-eclampsia, 
and the presence of disparate disease processes and thus 
pathophysiology might have reduced likelihood of 
identiﬁ cation of a treatment eﬀ ect. Our study in a 
homogeneous population of women with type 1 diabetes 
oﬀ ers additional insight into disease mechanisms. In 
principle, the notion that oxidative stress is implicated in 
pathogenesis of pre-eclampsia remains plausible, but the 
beneﬁ t of vitamin supplementation might be limited to 
women with vitamin depletion; however, this idea needs 
conﬁ rmation. Dietary intervention rich in various 
antioxidants might have beneﬁ ts that cannot be replicated 
by individual supplements. Alternatively, prescription of 
antioxidant vitamins at 8–22 weeks’ gestation might be too 
late to aﬀ ect the pathological process for most patients with 
diabetes. Antioxidant vitamins reduce rates of fetal 
malformation in rats with experimentally induced diabetes;30 
however, testing of such a hypothesis in patients would 
necessitate the introduction of supplementation before or 
around conception in a much larger number of women.
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Table 5: Rates of pre-eclampsia in 11 predeﬁ ned subgroups
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